Acceleron Pharma reported $109M in Current Liabilities for its second fiscal quarter of 2020.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Akebia Therapeutics AKBA:US $ 181.46M 14.32M
Alexion Pharmaceuticals ALXN:US $ 1120.1M 0.2M
Amgen AMGN:US $ 10523M 1304M
Bayer BAYN:GR € 36543M 14223M
Biomarin Pharmaceutical BMRN:US $ 813.3M 7.17M
Clovis Oncology CLVS:US $ 112M 10M
Dicerna Pharmaceuticals DRNA:US $ 239.77M 19.16M
Eli Lilly And LLY:US $ 11988.5M 621.7M
Exelixis EXEL:US $ 142M 2M
Gilead Sciences GILD:US $ 10564M 1685M
GlaxoSmithKline GSK:LN 23924M 1411M
Johnson & Johnson JNJ:US $ 38847M 2075M
Neurocrine Biosciences NBIX:US $ 573M 433M
Pfizer PFE:US $ 32723M 1167M
Ptc Therapeutics PTCT:US $ 201.84M 15.82M
Puma Biotechnology PBYI:US $ 94M 4M
Regeneron Pharmaceuticals REGN:US $ 3702.4M 1647.2M
Ultragenyx Pharmaceutical RARE:US $ 219.73M 22.87M
United Therapeutics UTHR:US $ 255M 47.7M
Vertex Pharmaceuticals VRTX:US $ 1798.64M 259.89M